Subscribe to RSS
DOI: 10.1055/s-0036-1597123
Relating Chronic Pelvic Pain and Endometriosis to Signs of Sensitization and Myofascial Pain and Dysfunction
Publication History
Publication Date:
03 January 2017 (online)
![](https://www.thieme-connect.de/media/srm/201701/lookinside/thumbnails/10-1055-s-0036-1597123_001049-1.jpg)
Abstract
Chronic pelvic pain is a frustrating symptom for patients with endometriosis and is frequently refractory to hormonal and surgical management. While these therapies target ectopic endometrial lesions, they do not directly address pain due to central sensitization of the nervous system and myofascial dysfunction, which can continue to generate pain from myofascial trigger points even after traditional treatments are optimized. This article provides a background for understanding how endometriosis facilitates remodeling of neural networks, contributing to sensitization and generation of myofascial trigger points. A framework for evaluating such sensitization and myofascial trigger points in a clinical setting is presented. Treatments that specifically address myofascial pain secondary to spontaneously painful myofascial trigger points and their putative mechanisms of action are also reviewed, including physical therapy, dry needling, anesthetic injections, and botulinum toxin injections.
-
References
- 1 Practice bulletin no. 114: management of endometriosis. Obstet Gynecol 2010; 116 (1) 223-236
- 2 Vercellini P, Fedele L, Aimi G, Pietropaolo G, Consonni D, Crosignani PG. Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum Reprod 2007; 22 (1) 266-271
- 3 Hsu AL, Sinaii N, Segars J, Nieman LK, Stratton P. Relating pelvic pain location to surgical findings of endometriosis. Obstet Gynecol 2011; 118 (2, Pt 1) 223-230
- 4 Institute of Medicine (US) Committee on Pain D, and Chronic Illness Behavior. The Anatomy and Physiology of Pain. In: Osterweis M, Kleinman A, Mechanic D, , eds. Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives. Washington, DC: National Academy Press; 1987: 123-145
- 5 Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009; 10 (9) 895-926
- 6 Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. Hum Reprod Update 2011; 17 (3) 327-346
- 7 Burnstock G. Autonomic neurotransmission: 60 years since sir Henry Dale. Annu Rev Pharmacol Toxicol 2009; 49: 1-30
- 8 May K, Becker CM. Endometriosis and angiogenesis. Minerva Ginecol 2008; 60 (3) 245-254
- 9 Raab S, Plate KH. Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol 2007; 113 (6) 607-626
- 10 Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006; 29: 507-538
- 11 Anaf V, Simon P, El Nakadi I , et al. Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum Reprod 2002; 17 (7) 1895-1900
- 12 Tokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in peritoneal endometriosis. Hum Reprod 2006; 21 (11) 3001-3007
- 13 Berkley KJ, Dmitrieva N, Curtis KS, Papka RE. Innervation of ectopic endometrium in a rat model of endometriosis. Proc Natl Acad Sci U S A 2004; 101 (30) 11094-11098
- 14 Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science 2005; 308 (5728) 1587-1589
- 15 Mechsner S, Kaiser A, Kopf A, Gericke C, Ebert A, Bartley J. A pilot study to evaluate the clinical relevance of endometriosis-associated nerve fibers in peritoneal endometriotic lesions. Fertil Steril 2009; 92 (6) 1856-1861
- 16 Snider WD, McMahon SB. Tackling pain at the source: new ideas about nociceptors. Neuron 1998; 20 (4) 629-632
- 17 Beste MT, Pfäffle-Doyle N, Prentice EA , et al. Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation. Sci Transl Med 2014; 6 (222) 222ra16
- 18 Anaf V, Chapron C, El Nakadi I, De Moor V, Simonart T, Noël JC. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril 2006; 86 (5) 1336-1343
- 19 Willard F., Basic Mechanisms of Pain. In: Audette JF, Bailey A. , eds. Integrative Pain Medicine: The Science and Practice of Complementary and Alternative Medicine in Pain Management. Totowa, NJ: Humana Press; 2008: 19-61
- 20 Sauer SK, Reeh PW, Bove GM. Noxious heat-induced CGRP release from rat sciatic nerve axons in vitro. Eur J Neurosci 2001; 14 (8) 1203-1208
- 21 Saria A. Substance P in sensory nerve fibres contributes to the development of oedema in the rat hind paw after thermal injury. Br J Pharmacol 1984; 82 (1) 217-222
- 22 Chiu IM, von Hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci 2012; 15 (8) 1063-1067
- 23 Gebhart GF. J.J. Bonica Lecture--2000: physiology, pathophysiology, and pharmacology of visceral pain. Reg Anesth Pain Med 2000; 25 (6) 632-638
- 24 Cervero F, Tattersall JE. Somatic and visceral sensory integration in the thoracic spinal cord. Prog Brain Res 1986; 67: 189-205
- 25 Jänig W, Morrison JF. Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. Prog Brain Res 1986; 67: 87-114
- 26 Schwartz ES, Gebhart GF. Visceral pain. Curr Top Behav Neurosci 2014; 20: 171-197
- 27 Rogers JR. Basic pelvic neuroanatomy. In: Steege JF, Metzger DA, Levy BS, , eds. Chronic Pelvic Pain: An Integrated Approach. Philadelphia: W.B. Saunders Company; 1998: 31-58
- 28 Sugiura Y, Tonosaki Y. Spinal organization of unmyelinated visceral afferent fibers in comparison with somatic afferent fibers. In: Gebhart GF, , ed. Visceral Pain: Progress in Pain Research and Management Series. Vol 5. Seattle, WA: IASP Press; 1995: 41-59
- 29 Nagabukuro H, Berkley KJ. Influence of endometriosis on visceromotor and cardiovascular responses induced by vaginal distention in the rat. Pain 2007; 132 (Suppl. 01) S96-S103
- 30 Jarrell J. Myofascial dysfunction in the pelvis. Curr Pain Headache Rep 2004; 8 (6) 452-456
- 31 Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In: Ward RC, Hruby RJ, Jerome JA, , eds. Foundations for Osteopathic Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003: 137-156
- 32 Patterson MM, Wurster RD. Neurophysiologic mechanisms of integration and disintegration. In: Ward RC, Hruby RJ, Jerome JA, , eds. Foundations for Osteopathic Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003: 1370-1156
- 33 Butrick CW. Discordant urination and defecation as symptoms of pelvic floor dysfunction. In: Howard FM, , ed. Pelvic Pain: Diagnosis and Management. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 280-299
- 34 Simons DG. Clinical and etiological update of myofascial pain from trigger points. J Musculoskeletal Pain 1996; 4 (1–2) 93-122
- 35 Simons DG, Travell JG, Simons LS. Myofascial Pain and Dysfunction: The Trigger Point Manual. Vol 1. 2nd ed. Baltimore, MD: Williams & Wilkins; 1999
- 36 Simons DG, Travell JG, Simons LS. Myofascial Pain and Dysfunction: The Trigger Point Manual. Vol 2. Baltimore, MD: Williams & Wilkins; 1992
- 37 Pastore EA, Katzman WB. Recognizing myofascial pelvic pain in the female patient with chronic pelvic pain. J Obstet Gynecol Neonatal Nurs 2012; 41 (5) 680-691
- 38 Stratton P, Khachikyan I, Sinaii N, Ortiz R, Shah J. Association of chronic pelvic pain and endometriosis with signs of sensitization and myofascial pain. Obstet Gynecol 2015; 125 (3) 719-728
- 39 Moldwin RM, Fariello JY. Myofascial trigger points of the pelvic floor: associations with urological pain syndromes and treatment strategies including injection therapy. Curr Urol Rep 2013; 14 (5) 409-417
- 40 Gerwin RD. Myofascial and visceral pain syndromes: visceral-somatic pain representations. J Musculoskeletal Pain 2002; 10 (1–2) 165-175
- 41 Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152 , (3 Suppl): S2-S15
- 42 Shah JP, Thaker N, Heimur J, Aredo JV, Sikdar S, Gerber L. Myofascial trigger points then and now: a historical and scientific perspective. PM R 2015; 7 (7) 746-761
- 43 Carter JE. Abdominal wall and pelvic myofascial trigger points. In: Howard FM, , ed. Pelvic Pain: Diagnosis & Management. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 314-358
- 44 Desai MJ, Saini V, Saini S. Myofascial pain syndrome: a treatment review. Pain Ther 2013; 2 (1) 21-36
- 45 Bedaiwy MA, Patterson B, Mahajan S. Prevalence of myofascial chronic pelvic pain and the effectiveness of pelvic floor physical therapy. J Reprod Med 2013; 58 (11-12) 504-510
- 46 Ay S, Evcik D, Tur BS. Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial. Clin Rheumatol 2010; 29 (1) 19-23
- 47 Montenegro ML, Braz CA, Rosa-e-Silva JC, Candido-dos-Reis FJ, Nogueira AA, Poli-Neto OB. Anaesthetic injection versus ischemic compression for the pain relief of abdominal wall trigger points in women with chronic pelvic pain. BMC Anesthesiol 2015; 15: 175
- 48 Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. Neurourol Urodyn 2007; 26 (1) 59-62
- 49 Kim DS, Jeong TY, Kim YK, Chang WH, Yoon JG, Lee SC. Usefulness of a myofascial trigger point injection for groin pain in patients with chronic prostatitis/chronic pelvic pain syndrome: a pilot study. Arch Phys Med Rehabil 2013; 94 (5) 930-936
- 50 Karp BI. Botulinum toxin treatment of occupational and focal hand dystonia. Mov Disord 2004; 19 (Suppl. 08) S116-S119
- 51 Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ 2000; 320 (7228) 161-165
- 52 Göbel H, Heinze A, Reichel G, Hefter H, Benecke R ; Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006; 125 (1-2) 82-88
- 53 Harden RN, Cottrill J, Gagnon CM , et al. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache 2009; 49 (5) 732-743
- 54 Kwanchuay P, Petchnumsin T, Yiemsiri P, Pasuk N, Srikanok W, Hathaiareerug C. Efficacy and safety of single botulinum toxin type A (Botox®) injection for relief of upper trapezius myofascial trigger point: a randomized, double-blind, placebo-controlled study. J Med Assoc Thai 2015; 98 (12) 1231-1236
- 55 Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010; 79: 591-617
- 56 Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006; 108 (4) 915-923
- 57 Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med 2009; 6 (9) 2523-2537
- 58 Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104 (5, Pt 1) 922-925
- 59 Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 2004; 44 (1) 46-50
- 60 Bertolasi L, Frasson E, Cappelletti JY, Vicentini S, Bordignon M, Graziottin A. Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol 2009; 114 (5) 1008-1016
- 61 Nesbitt-Hawes EM, Won H, Jarvis SK, Lyons SD, Vancaillie TG, Abbott JA. Improvement in pelvic pain with botulinum toxin type A—single vs. repeat injections. Toxicon 2013; 63: 83-87
- 62 Morrissey D, El-Khawand D, Ginzburg N, Wehbe S, O'Hare III P, Whitmore K. Botulinum toxin A injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: a 6-month prospective pilot study. Female Pelvic Med Reconstr Surg 2015; 21 (5) 277-282
- 63 Adelowo A, Hacker MR, Shapiro A, Modest AM, Elkadry E. Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg 2013; 19 (5) 288-292
- 64 Romito S, Bottanelli M, Pellegrini M, Vicentini S, Rizzuto N, Bertolasi L. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 2004; 58 (3) 164-167
- 65 Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin injections. Lancet 1997; 349 (9047) 252-253
- 66 Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG. The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG 2005; 112 (2) 247-249
- 67 Park AJ, Paraiso MF. Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia. Obstet Gynecol 2009; 114 (2, Pt 2) 484-487
- 68 Pellett S, Yaksh TL, Ramachandran R. Current status and future directions of botulinum neurotoxins for targeting pain processing. Toxins (Basel) 2015; 7 (11) 4519-4563
- 69 Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol (1985) 2005; 99 (5) 1977-1984
- 70 Shah JP, Danoff JV, Desai MJ , et al. Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. Arch Phys Med Rehabil 2008; 89 (1) 16-23
- 71 Shah JP, Gilliams EA. Uncovering the biochemical milieu of myofascial trigger points using in vivo microdialysis: an application of muscle pain concepts to myofascial pain syndrome. J Bodyw Mov Ther 2008; 12 (4) 371-384